Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - iron-sucrose complex - unknown - iron-sucrose complex mineral- iorn base active 0.0 - active constituent

Kenija - anglų - Pharmacy and Poisons Board

claris injectables limited off mombasa road, masai road, nairobi kenya - iron sucrose - solution for infusion - 20 mg/ml - antianemic preparations - iron preparations: iron

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron sucrose 540 mg/ml equivalent to iron 20 mg/ml - solution for injection - 20 mg/ml - active: iron sucrose 540 mg/ml equivalent to iron 20 mg/ml excipient: water for injection - venofer is indicated for the treatment of iron deficiency in the following indications: · where there is a clinical need for a rapid iron supply, · in patients who cannot tolerate oral iron therapy or who are non-compliant, · in active inflammatory bowel disease where oral iron preparations are ineffective.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

american regent, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

fresenius medical care holdings, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - iron-sucrose complex - parenteral liquid/solution/suspension - iron-sucrose complex mineral- iorn base active 20.0 mg - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - iron deficiency | anaemia

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

preferredpharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 10 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii 1 as follows: generalized, persistent anxiety (of at least 1 mont